Photovoltaic Potential Estimation by Means of Data Mining in Four Colombian Cities

En este trabajo se analiza el potencial fotovoltaico en cuatro ciudades colombianas, gracias a la información recopilada en Bogotá, Cúcuta, Manizales y Pasto. La metodología propuesta utiliza técnicas de agrupamiento que se implementan mediante el uso del software MATLAB®. Se exponen dos algoritmos de comparación presentados: K-means y Fuzzy C-means, y uno de visualización que es el Análisis de componentes principales (PCA) que ayuda en el análisis de resultados. Este artículo muestra estudios previos relacionados con la minería de datos y se describen los algoritmos mencionados anteriormente. Por otro lado, los resultados y discusión más relevantes, que corresponden a la factibilidad de implementación de las micro-redes, se determinan mediante el cálculo del Factor de Capacidad.This work analyzes the photovoltaic potential of four cities in Colombia—Bogotá, Cúcuta, Manizales, and Pasto—using information collected in situ and data mining strategies. The methodology of this study is based on clustering techniques implemented in MATLAB® software. Two comparison algorithms are presented: K-means, Fuzzy C-means, and an additional visualization algorithm, i.e., Principal Component Analysis (PCA), which supports results analysis. This article explores published studies regarding data mining and it describes the previously mentioned algorithms.  On the other hand, the most relevant results and discussion, which are related to the feasibility of implementation of micro-grids, are determined by calculating the Capacity Factor

Body composition, nutritional profile and muscular fitness affect bone health in a sample of schoolchildren from Colombia: The Fuprecol Study

This is the final version of the article. Available from the publisher via the DOI in this record.The objective of the present study is to investigate the relationships between body composition, nutritional profile, muscular fitness (MF) and bone health in a sample of children and adolescents from Colombia. Participants included 1118 children and adolescents (54.6% girls). Calcaneal broadband ultrasound attenuation (c-BUA) was obtained as a marker of bone health. Body composition (fat mass and lean mass) was assessed using bioelectrical impedance analysis. Furthermore height, weight, waist circumference and Tanner stage were measured and body mass index (BMI) was calculated. Standing long-jump (SLJ) and isometric handgrip dynamometry were used respectively as indicators of lower and upper body muscular fitness. A muscular index score was also computed by summing up the standardised values of both SLJ and handgrip strength. Dietary intake and degree of adherence to the Mediterranean diet were assessed by a 7-day recall questionnaire for food frequency and the Kidmed questionnaire. Poor bone health was considered using a z-score cut off of ≤−1.5 standard deviation. Once the results were adjusted for age and Tanner stage, the predisposing factors of having a c-BUA z-score ≤−1.5 standard deviation included being underweight or obese, having an unhealthy lean mass, having an unhealthy fat mass, SLJ performance, handgrip performance, and unhealthy muscular index score. In conclusion, body composition (fat mass and lean body mass) and MF both influenced bone health in a sample of children and adolescents from Colombia. Thus promoting strength adaptation and preservation in Colombian youth will help to improve bone health, an important protective factor against osteoporosis in later life.: We would like to acknowledge to Bogota District Education Department for supporting data collection for this study. The authors also thank the participating Bogota District students, teachers, schools, and staff. The “FUPRECOL Study” was possible given the financial support provided by the Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología “Francisco José de Caldas” COLCIENCIAS (Contract Number 671-2014 Code 122265743978). Also, during the completion of this paper, AG-H was visiting researchers at the University of Rosario (CEMA, Bogotá, Colombia), supported with grants awarded by Proyectos Basales y Vicerrectoría de Investigación, Desarrollo e Innovación” (Universidad de Santiago de Chile, USACH)

Investigating Safety And Preliminary Efficacy Of Afm13 Plus Pembrolizumab In Patients With Relapsed/Refractory Hodgkin Lymphoma After Brentuximab Vedotin Failure

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/149522/1/hon134_2629.pd

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

BACKGROUND: Brentuximab vedotin is a CD30-directed antibody-drug conjugate. Retreatment with brentuximab vedotin monotherapy was investigated in patients with CD30-positive Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (ALCL) who relapsed after achieving complete or partial remission (CR or PR) with initial brentuximab vedotin therapy in a previous study (ClinicalTrials.gov NCT00947856). METHODS: Twenty-one patients with HL and 8 patients with systemic ALCL were retreated; 3 patients with systemic ALCL were retreated twice. Patients generally received brentuximab vedotin 1.8 mg/kg intravenously approximately every 3 weeks over 30 minutes as an outpatient infusion. The primary objectives of this study were to assess safety and to estimate antitumor activity of brentuximab vedotin retreatment. RESULTS: The objective response rate was 60% (30% CR) in HL patients and 88% (63% CR) in systemic ALCL patients. The estimated median duration of response for patients with an objective response was 9.5 months (range, 0.0+ to 28.0+ months) at the time of study closure. Of the 19 patients with objective response, 7 patients had not had an event of disease progression or death at the time of study closure; duration of response for these patients ranged from 3.5 to 28 months. Of the 11 patients with CR, 45% had response durations of over 1 year. Adverse events (AEs) occurring in ≥25% of patients during the retreatment period were generally similar in type and frequency to those observed in the pivotal trials of brentuximab vedotin monotherapy, with the exception of peripheral neuropathy, which is known to have a cumulative effect. Grade 3 or higher events were observed in 48% of patients; these were generally transient and managed by dose modifications or delays. Deaths due to AEs occurred in 3 HL patients; none were considered to be related to brentuximab vedotin retreatment. DISCUSSION: With the exception of a higher rate of peripheral motor neuropathy, retreatment with brentuximab vedotin was associated with similar side effects seen in the pivotal trials. CONCLUSIONS: Retreatment with brentuximab vedotin monotherapy is associated with response rates in 68% (39% CR) of patients with relapsed HL and systemic ALCL. TRIAL REGISTRATION: United States registry and results database ClinicalTrials.gov NCT00947856

Detección, rastreo y reconstrucción tridimensional de marcadores pasivos para análisis de movimiento humano. Cinemed III

Uno de los desafíos más importantes cuando se desarrolla un sistema de análisis de movimiento es la reconstrucción tridimensional, ya que este proceso involucra una serie de algoritmos que tienen que trabajar de forma sinérgica con el fin de reconstruir el movimiento correctamente y aminorando el número de intervenciones del usuario. Por esta razón en este artículo, se realiza una descripción detallada de un esquema para la reconstrucción tridimensional del movimiento humano mediante la integración de diferentes algoritmos que a su vez minimizan la intervención del usuario durante el proceso (Sistema de análisis de movimiento CineMED III). Para probar el desempeño del esquema propuesto se realizaron tres pruebas experimentales; un marcador estático, barra con dos marcadores en movimiento y dispositivo de medición de errores. Obteniendo finalmente que CineMED III posee un desempeño cercano al de los sistemas comerciales, mostrando en las pruebas realizadas con la barra un error absoluto medio menor respecto al sistema Vicon, pero mayor con respecto al sistema Elite y en las pruebas con el dispositivo un valor de RMS mayor respecto al sistema Ariel, pero un error máximo menor respecto a este ultimo sistema, sin embargo la aproximación propuesta presenta problemas cuando se ocluyen marcadores por largos periodos de tiempo y cuando se cruza la trayectoria de dos marcadores. Para resolver dichos problemas se propone adicionar algunas cámaras al sistema y así obtener información redundante de la captura del movimiento.One of the most important challenges when a movement analysis system is been developed is the three-dimensional reconstruction. This process involves several algorithms that must work synergistically in order to reconstruct the movement correctly and decreasing the user interventions. For this reason this paper describes in detail a new methodology to carry out the three-dimensional reconstruction of the human movement through the join of different algorithms decreasing the user input during the process (movement analysis system CineMED III). To analyze and evaluate the performance achieved using the methodology proposed, three experimental tests were carried out; a static marker test, bar with two markers in motion and using an error measurement device. CineMED III finally has a performance close to that of commercial systems, showing in the tests performed with the bar a lower average absolute error for the Vicon system, but higher with respect to the Elite system and testing the device with a value of RMS more about the Ariel system, but a smaller maximum error on the latter system., However, the proposed approach presents problems when markers are occluded for long periods of time and when the paths of two markers intersect. To solve these problems, it is proposed to add some cameras into the system to obtain redundant information from the motion capture

A phase 1 trial of SGNâ CD70A in patients with CD70â positive, metastatic renal cell carcinoma

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/148406/1/cncr31912.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/148406/2/cncr31912_am.pd

TBCRC 019: A phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple negative breast cancer

Purpose: Tigatuzumab (TIG), an agonistic anti-DR5 antibody, triggers apoptosis in DR5+ human tumor cells without crosslinking. TIG has strong in vitro/in vivo activity against basal-like breast cancer cells enhanced by chemotherapy agents. This study evaluates activity of TIG and chemotherapy in patients with metastatic triple-negative breast cancer (TNBC). Experimental Design: Randomized 2:1 phase II trial of albumin-bound paclitaxel (nab-PAC) ± TIG in patients with TNBC stratified by prior chemotherapy. Patients received nab-PAC weekly × 3 ± TIG every other week, every 28 days. Primary objective was within-arm objective response rate (ORR). Secondary objectives were safety, progression-free survival (PFS), clinical benefit, and TIG immunogenicity. Metastatic research biopsies were required. Results: Among 64 patients (60 treated; TIG/nab-PAC n = 39 and nab-PAC n = 21), there were 3 complete remissions (CR), 8 partial remissions (PR; 1 almost CR), 11 stable diseases (SD), and 17 progressive diseases (PD) in the TIG/nab-PAC arm (ORR, 28%), and no CRs, 8 PRs, 4 SDs, and 9 PDs in the nab-PAC arm (ORR, 38%). There was a numerical increase in CRs and several patients had prolonged PFS (1,025+, 781, 672, 460, 334) in the TIG/nab-PAC arm. Grade 3 toxicities were 28% and 29%, respectively, with no grade 4–5. Exploratory analysis suggests an association of ROCK1 gene pathway activation with efficacy in the TIG/nab-PAC arm. Conclusions: ORR and PFS were similar in both. Preclinical activity of TIG in basal-like breast cancer and prolonged PFS in few patients in the combination arm support further investigation of anti-DR5 agents. ROCK pathway activation merits further evaluation